# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cyclacel Pharmaceuticals (NASDAQ:CYCC) reported quarterly losses of $(2.27) per share which beat the analyst consensus estimate...
Roth MKM analyst Jonathan Aschoff maintains Cyclacel Pharmaceuticals (NASDAQ:CYCC) with a Buy and lowers the price target fr...